If you or a loved one took Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Rybelsus, Trulicity, or Victoza and developed gastroparesis (stomach paralysis), severe gastrointestinal injuries, sudden vision loss, pancreatitis, or another serious complication, you may be eligible to file a claim in the rapidly expanding GLP-1 mass tort.

This is the biggest emerging pharmaceutical mass tort of 2025-2026, with thousands of new cases filed each month and bellwether trials on the horizon. At Sky Law Firm, we’re actively investigating Ozempic and GLP-1 injury claims for clients across Florida and nationwide.

Below is everything you need to know about the GLP-1 lawsuits, whether you qualify, what compensation may be available, and why you must act before the statute of limitations bars your claim.

Time-sensitive notice: The statute of limitations for pharmaceutical injury claims in Florida is generally two to four years from the date of discovery of injury. New plaintiffs are joining MDL 3094 every week — but bellwether trials are expected to begin in late 2026 or 2027, and global settlement discussions could close the litigation to new claimants. Free, no-obligation case evaluation: contact Sky Law Firm today.

Quick Summary: The 2026 GLP-1 Mass Tort at a Glance

What Are Ozempic and GLP-1 Receptor Agonists?

Ozempic, Wegovy, Mounjaro, and the other drugs at the center of the 2026 mass tort all belong to a class of medications called glucagon-like peptide-1 receptor agonists — commonly shortened to GLP-1 RAs or simply “GLP-1s.”

These drugs were originally developed to treat type 2 diabetes by mimicking the natural GLP-1 hormone, which regulates blood sugar by stimulating insulin release and slowing digestion. Beginning around 2021, however, the public discovered a powerful side effect: dramatic weight loss. Demand exploded, prescriptions skyrocketed, and Ozempic became a household name — promoted by celebrities, influencers, and even appearing on the red carpet at the Oscars.

The three primary active ingredients in the GLP-1 class are:

• Semaglutide — sold as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral semaglutide)
• Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (weight loss); technically a dual GLP-1/GIP agonist
• Liraglutide — sold as Victoza (diabetes) and Saxenda (weight loss)
• Dulaglutide — sold as Trulicity (diabetes)

These drugs work by slowing gastric emptying — the speed at which food leaves the stomach. That mechanism is precisely why they suppress appetite and produce weight loss. Unfortunately, it’s also why thousands of patients have developed serious, sometimes permanent gastrointestinal injuries.

Drugs Covered by the 2026 GLP-1 Mass Tort

If you took any of the following medications and developed a covered injury, you may have a claim:

Compounded semaglutide and tirzepatide prescribed through telehealth weight-loss platforms may also qualify, depending on the source and circumstances. If you used a compounded version, bring all documentation to your case evaluation.

Reported Injuries: What GLP-1 Drugs Have Done to Patients

The injuries linked to Ozempic and other GLP-1 drugs are not minor side effects — they are serious, often permanent, and in some cases life-threatening medical conditions. Here are the principal injuries currently being litigated in MDL 3094:

1. Gastroparesis (Stomach Paralysis) — The Most Common Claim

Gastroparesis is a chronic condition in which the stomach loses the ability to empty itself normally. Food sits in the stomach for hours or even days, causing:

• Severe, persistent nausea and vomiting
• Abdominal pain and bloating
• Inability to keep food or liquids down
• Dramatic, unwanted weight loss
• Malnutrition and dehydration
• Need for feeding tubes in severe cases

Because GLP-1 drugs work by slowing gastric emptying on purpose, they can essentially “freeze” the stomach. For some patients, that paralysis does not reverse when they stop the medication. Plaintiffs report persistent gastroparesis lasting months or years after discontinuation.

This is the single largest category of GLP-1 lawsuits filed to date.

2. Severe Nausea and Cyclic Vomiting

Beyond classic gastroparesis, many plaintiffs experience intractable, debilitating nausea and vomiting episodes that require emergency room visits, hospitalization, IV fluids, and ongoing medication.

3. Intestinal Blockage / Ileus

GLP-1 drugs have been linked to intestinal obstruction and ileus — a condition where the bowels stop moving food through the intestines. This often requires:

• Hospitalization
• Nasogastric (NG) tube placement
• Surgical intervention to clear the blockage
• Prolonged recovery

In September 2023, the FDA updated Ozempic’s label to include a warning about ileus — but only after thousands of patients had already been injured.

4. NAION (Sudden Vision Loss / Blindness)

In July 2024, a peer-reviewed study published in JAMA Ophthalmology found that patients taking semaglutide had a significantly higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) — a condition that causes sudden, often permanent vision loss in one or both eyes.

NAION is sometimes called a “stroke of the eye” and there is no cure. The 2024 study has prompted a wave of new lawsuits and is expected to be a major component of the bellwether selection process.

5. Pancreatitis

Acute and chronic pancreatitis — inflammation of the pancreas — has been reported in GLP-1 users. Symptoms include severe upper abdominal pain, fever, nausea, and elevated pancreatic enzymes. Pancreatitis can be life-threatening and may lead to long-term complications including diabetes, pancreatic insufficiency, and increased cancer risk.

6. Pulmonary Aspiration During Anesthesia

Because GLP-1 drugs slow stomach emptying, patients undergoing surgery face elevated risk of pulmonary aspiration — inhaling stomach contents into the lungs while sedated. The American Society of Anesthesiologists issued specific pre-operative guidance in 2023 advising patients to stop GLP-1s a week or more before surgery. Patients who suffered aspiration injuries during procedures may have additional claims.

7. Suicidal Ideation and Mental Health Effects

European regulators began investigating reports of suicidal ideation and self-harm in GLP-1 users in 2023. While the FDA has so far declined to add a black-box warning, a subset of plaintiffs are pursuing claims for psychiatric injuries.

8. Other Reported Injuries

• Gallbladder disease and gallstones requiring removal
• Kidney injury and acute kidney failure
• Deep vein thrombosis (DVT)
• Severe hair loss
• Thyroid tumors (animal studies have shown risk)

What Did the Manufacturers Know — and When?

The legal foundation of the GLP-1 mass tort is failure to warn. Plaintiffs allege that Novo Nordisk and Eli Lilly knew, or should have known, about the serious risks of their drugs but failed to adequately warn doctors and patients.

Internal documents, FDA adverse-event reports (FAERS), and published literature support several key allegations:

• Pre-market knowledge of delayed gastric emptying. The mechanism that causes gastroparesis was well-understood by the manufacturers from clinical trials.
• Adverse event signals ignored. FAERS data shows hundreds of gastroparesis and ileus reports years before label updates.
• Aggressive off-label marketing for weight loss. Ozempic, in particular, was promoted heavily for cosmetic weight loss before Wegovy received its weight-loss indication.
• Inadequate warnings on labeling. Until late 2023, Ozempic’s label did not warn about ileus. NAION still does not appear in current U.S. labeling as of early 2026.
• Failure to update warnings as evidence accumulated. Manufacturers have a continuing duty under federal and state law to update labels as risk information emerges. Plaintiffs argue that duty was breached.

These are the same theories of liability that produced multi-billion-dollar verdicts and settlements in prior pharmaceutical mass torts including Vioxx, Zantac, and Tylenol/acetaminophen litigation.

MDL 3094: The Federal Mass Tort Explained

In February 2024, the Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal GLP-1 lawsuits into MDL 3094 — In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, assigned to the U.S. District Court for the Eastern District of Pennsylvania, before the Honorable Karen Spencer Marston.

What is an MDL?

A Multidistrict Litigation consolidates federal cases that share common factual questions before a single judge for pretrial proceedings. This streamlines discovery, expert development, and pretrial motions — without merging the cases into a class action. Each plaintiff retains their individual claim with case-specific damages.

After common pretrial work, a small number of “bellwether” cases go to trial. Those verdicts inform settlement negotiations for the entire MDL inventory.

Where MDL 3094 Stands in 2026

• Active cases: Over 2,500 individual plaintiff complaints, growing by hundreds per month
• Plaintiffs’ Steering Committee (PSC): Formed in 2024 with experienced mass tort counsel
• Master Complaint and Short Form Complaint: In place, allowing efficient case filing
• Discovery: Document production from Novo Nordisk and Eli Lilly is well underway
• Bellwether selection: Initial pool established; case-specific discovery proceeding
• First bellwether trials: Expected late 2026 through 2027
• Global settlement: Possible 2027-2028, depending on bellwether outcomes

Why Bellwether Trials Matter

Bellwether trials are the pivotal moment in any mass tort. A series of plaintiff verdicts can pressure defendants into nine- or ten-figure settlements. Conversely, defense verdicts can deflate case values across the entire MDL. The plaintiffs whose cases are selected as bellwethers — and the lawyers who try them — set the value of every other case.

That’s why representation by an attorney with active mass-tort trial experience and direct PSC relationships matters more than choosing a high-volume settlement mill.

Are You Eligible? Sky Law’s GLP-1 Lawsuit Criteria

To qualify for a GLP-1 lawsuit through Sky Law Firm, you generally need to meet three criteria:

Criterion 1: You Took a Covered GLP-1 Drug

You used one of the following medications, by prescription or compounded version:
– Ozempic, Wegovy, Rybelsus
– Mounjaro, Zepbound
– Saxenda, Victoza
– Trulicity

Use can be for any duration — even short-term use has produced eligible injuries — but longer use generally strengthens causation.

Criterion 2: You Were Diagnosed With a Covered Injury

You received a medical diagnosis of one of the following:
– Gastroparesis
– Cyclic vomiting syndrome / intractable vomiting
– Intestinal obstruction or ileus
– NAION (non-arteritic anterior ischemic optic neuropathy) or other sudden vision loss
– Acute or chronic pancreatitis
– Pulmonary aspiration during a surgical procedure
– Gallbladder disease requiring removal (cholecystectomy)
– Other significant injury linked to GLP-1 use

The diagnosis should be supported by medical records — endoscopy, gastric emptying study (GES), imaging, ophthalmology workup, hospital admission records, etc.

Criterion 3: You Can Document Use

We need to be able to prove you took the drug. Acceptable documentation includes:
– Prescription records from your pharmacy
– Insurance Explanation of Benefits (EOBs) showing fills
– Telehealth platform records (Hims/Hers, Ro, Found, Calibrate, etc.)
– Medical records from the prescribing doctor
– Compounding pharmacy invoices

Don’t worry if you don’t have all of this on hand. Sky Law Firm’s intake team will help you obtain pharmacy records and medical records as part of our case workup — at no cost to you.

Statute of Limitations: Why Florida Plaintiffs Must Act Now

Florida’s statute of limitations for product liability is generally four years under Fla. Stat. § 95.11(3), and for wrongful death it is two years under Fla. Stat. § 95.11(4). Critically, Florida applies the discovery rule — the clock starts running when the plaintiff knew, or reasonably should have known, that an injury was caused by the drug.

In practice, that often means the clock starts when:
– You were diagnosed with gastroparesis (or another covered injury), AND
– You had reason to connect the injury to GLP-1 use (often the date of a doctor’s discussion or a news report on Ozempic injuries)

But here’s the catch: defendants will argue that the clock started running earlier than you think. Every day you wait, the risk grows that a court will rule your claim is time-barred.

There is also a more practical deadline: the MDL itself. Once bellwether trials produce verdicts and a global settlement framework is negotiated, the defendants will press for a claims registration cutoff. Plaintiffs who haven’t filed by that cutoff are typically excluded from the settlement matrix. Filing late often means recovering nothing.

Bottom line: if you suspect you have a GLP-1 injury, get evaluated now. A free consultation costs nothing. Waiting could cost everything.

Compensation: What Is an Ozempic Lawsuit Worth?

No one can guarantee a specific settlement amount — that would be unethical and, in most jurisdictions, illegal. But based on prior pharmaceutical mass torts with comparable fact patterns (Zantac, Bayer’s Roundup, Tylenol autism MDL valuations, Pradaxa), plaintiffs’ attorneys broadly estimate GLP-1 case values in the following ranges:

These are projections, not promises. Actual recovery depends on the strength of your medical records, the duration and dose of GLP-1 use, the severity of your injury, your age and earning capacity, and the ultimate outcome of bellwether trials and settlement negotiations.

What you can count on with Sky Law Firm: we work on a contingency-fee basis. You pay nothing unless we recover for you. No upfront fees. No hourly billing. No costs out of your pocket.

How to File a GLP-1 Lawsuit With Sky Law Firm

Here’s exactly what happens when you contact us about an Ozempic or GLP-1 claim:

Step 1: Free Case Evaluation (Same Day)

Call us, fill out our online form, or text our intake team. A Sky Law attorney or qualified intake specialist will speak with you within 24 hours — often the same day. We’ll ask:
– Which GLP-1 drug(s) you took, when, and at what dose
– What injury you suffered and when you were diagnosed
– Where you were treated
– Whether you have prescription and medical records

Step 2: Records Collection

If your case looks viable, we’ll send you HIPAA authorizations and collect your medical and pharmacy records ourselves. Most clients don’t need to lift a finger beyond signing the forms.

Step 3: Medical & Legal Review

Our team — including consulting physicians and pharmacology experts — reviews the records to confirm:
– Documented use of the GLP-1 drug
– A qualifying injury diagnosis
– A plausible causal link
– That the statute of limitations has not expired

Step 4: Filing Your Claim

If we accept your case, we file a Short Form Complaint directly into MDL 3094 in the Eastern District of Pennsylvania. You become a plaintiff in the consolidated litigation and your claim is preserved against the statute of limitations.

Step 5: Discovery and Plaintiff Fact Sheet (PFS)

You’ll complete a Plaintiff Fact Sheet — a detailed questionnaire about your medical history and GLP-1 use. We help you complete it. This is the most “work” you’ll do as a plaintiff.

Step 6: Bellwether or Settlement

Your case proceeds toward either bellwether trial selection (rare — only a handful of cases are picked) or, much more commonly, inclusion in a global settlement once one is reached. Sky Law negotiates aggressively for the highest tier placement your injury supports.

Step 7: Distribution

Once you accept a settlement, funds are distributed through a court-supervised qualified settlement fund. You receive your check, lien holders are resolved, and the case closes.

Why Choose a Florida Firm Over a National Settlement Mill?

You’ve seen the late-night TV ads and Facebook posts: “Did you take Ozempic? Call now!” Most of those ads come from national lead-generation operations and high-volume settlement mills that:

• Buy your case from a marketing company
• Sign you up by text message with no actual attorney conversation
• Sell or refer your case 2-3 times before it’s ever filed
• Drop you into a settlement matrix at the lowest possible tier
• Take 40% plus expenses, leaving you with a fraction of what you deserve

Sky Law Firm works differently.

• Local Florida representation. Real attorneys you can meet with in person in Miami. We answer our own phones.
• Florida-licensed and experienced in Florida courts. State-court venue may be preferable for some Florida plaintiffs, and we know the difference.
• Direct MDL filing. Your case goes into MDL 3094 under our firm name — not resold to a third party.
• Pharmaceutical injury focus. Our pharmaceutical injury practice is a core firm area, not a side hustle.
• Aggressive tier placement advocacy. When the settlement matrix is published, we fight for the highest tier your records support. That can mean six figures of difference.
• Personal attention. You will speak with an actual attorney about your case — repeatedly, throughout the process.

When the settlement matrix lands, the difference between a Tier 1 and a Tier 3 placement can be hundreds of thousands of dollars. The firm that fights for your tier is the firm that determines your outcome. Choose carefully.

Frequently Asked Questions: Ozempic Lawsuits in Florida

1. I took Ozempic for diabetes, not weight loss. Can I still sue?

Yes. Eligibility is based on what injury you suffered, not why you took the drug. Diabetic and weight-loss patients alike are filing — and in fact, diabetic patients with documented long-term use often have stronger causation evidence.

2. I only took Ozempic for a few months. Is that long enough?

Possibly. There is no fixed minimum duration. Some plaintiffs developed gastroparesis after just a few weeks of use. The key questions are: did you have the injury, can you document the use, and is the timeline medically plausible? Let our team evaluate it for free.

3. I bought compounded semaglutide from a telehealth company. Does that count?

Often, yes. Compounded GLP-1 cases are being evaluated and many are being accepted into the MDL, particularly where the active ingredient was sourced from FDA-registered facilities. Bring all your telehealth records, invoices, and prescription documentation.

4. What if my doctor told me my gastroparesis is unrelated to Ozempic?

Get a second opinion — ideally from a gastroenterologist familiar with GLP-1 complications. Many primary care doctors and even specialists are still catching up on the literature. Your attorney will also retain independent medical experts to evaluate causation.

5. Does Florida have its own GLP-1 lawsuits, separate from the MDL?

There is no consolidated state-court mass tort in Florida at this time. Most Florida plaintiffs file directly into federal MDL 3094. In some cases, individual state-court filings may make sense — Sky Law evaluates this on a case-by-case basis.

6. How long will my case take?

Mass tort timelines are long. Realistic expectations: 2-4 years from filing to settlement distribution. Bellwether outcomes in 2026-2027 will largely determine when global settlement is reached.

7. Will I have to go to court or testify?

For the vast majority of plaintiffs, no. Only a small number of bellwether plaintiffs see the inside of a courtroom. Most plaintiffs complete a Plaintiff Fact Sheet and possibly a deposition, but never appear at trial.

8. How much does it cost to hire Sky Law Firm?

Nothing upfront. We work on a contingency fee — we are paid only if we recover for you, as a percentage of the settlement. All case expenses (records, experts, filing fees) are advanced by the firm and reimbursed only out of any recovery. If we don’t win, you don’t pay.

9. What if my loved one died from a GLP-1 complication?

You may have a wrongful death claim under the Florida Wrongful Death Act (Fla. Stat. § 768.16 et seq.). The statute of limitations for wrongful death in Florida is two years, which is shorter than the product-liability period — so do not delay.

10. I’m in the middle of treatment. Should I stop taking Ozempic before suing?

Never stop a prescribed medication without talking to your doctor. Your decision to continue or discontinue treatment is medical, not legal — and it does not affect your eligibility to sue. We have many active plaintiffs who continue GLP-1 therapy under their doctor’s supervision.

11. Will suing affect my health insurance or future medical care?

No. Filing a product-liability lawsuit against a drug manufacturer has no impact on your insurance coverage or your relationship with your doctors. Your medical providers are not parties to the lawsuit.

12. What’s the deadline to join the GLP-1 mass tort?

Two deadlines apply:

1. Florida statute of limitations — generally 4 years from discovery of injury for product liability, 2 years for wrongful death.
2. MDL claims-registration cutoff — not yet set, but expected once a global settlement framework is finalized (likely 2027-2028). After the cutoff, new plaintiffs are typically barred from participating.

Either deadline can end your claim. Don’t gamble. Get a free evaluation today.

Take Action: Get Your Free Ozempic Case Evaluation

If you’ve been injured by Ozempic, Wegovy, Mounjaro, or another GLP-1 drug, the time to act is now. Bellwether trials are around the corner, the settlement clock is ticking, and Florida’s statute of limitations does not pause for anyone.

Free, No-Obligation Case Evaluation

• Call Sky Law Firm: Click here for our intake number
• Online intake form: Submit your case details
• Available 24/7 — bilingual intake (English and Spanish)
• No fees unless we win
• Florida-licensed attorneys with active mass-tort experience

You owe Novo Nordisk and Eli Lilly nothing. They owe you answers, accountability, and compensation. Sky Law Firm is here to make them deliver.

Related Reading

• Pharmaceutical Injury Practice Area
• How Mass Tort Settlements Are Distributed
• Florida Statute of Limitations on Drug Injury Claims
• What to Expect When You File a Pharma Injury Claim

This article is for informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship with Sky Law Firm. Every case is unique. Past results do not guarantee future outcomes. For advice on your specific situation, contact a licensed Florida attorney.

Reviewed and approved for publication: April 14, 2026.